Clinical Trial

Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.

Study acronym: HB0043-HS-0-01
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 7, 2026 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe HS.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-03-19; most recent amendment 2026-01-04.
Status change: Not Yet Recruiting → Recruiting 2025-04-03
Trial Details
NCT Number NCT06895499
Lead Sponsor Shanghai Huaota Biopharmaceutical Co., Ltd.
Collaborators: Dermatology Hospital affiliated to Shandong First Medical University
Conditions Hidradenitis Suppurativa
Enrollment 15 participants
Start Date 2025-03-19
Primary Completion 2026-01-30 (estimated)
Study Completion 2026-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-07